TABLE 1.
Treatment indications for chronic hepatitis B according to the most recent recommendations of the EASL, AASLD, and WHO.
| Organization | Grade | HBeAg | HBV‐DNA (IU/mL) | ALT a | Fibrosis | Other/comment |
|---|---|---|---|---|---|---|
| EASL (CPG 2017) | Strong | (+) or (−) | >20,000 | >2 × ULN | Any | |
| Strong | (+) or (−) | >2000 | >ULN | ≥F2 | HBV‐DNA + one other criteria | |
| Strong | (+) or (−) | Detectable | Any | Any | Cirrhosis | |
| Weak | (+) | >20,000 | ≤ULN | Any | Age: >30 years | |
| Weak b | (+) or (−) | Any | Any | Any | Family history of HCC | |
| AASLD (CPG 2018) | ‐ | (+) | >20,000 | >2 × ULN | Any | |
| ‐ | (+) | >20,000 | >ULN | ≥F2 | ||
| ‐ | (−) | >2000 | >2 × ULN | Any | ||
| ‐ | (−) | >2000 | >ULN | ≥F2 | HBV‐DNA + one other criteria | |
| (+) or (−) | Detectable | Any | Any | Cirrhosis | ||
| WHO (CPG 2015) | Strong | (+) or (−) | Any | Any | Any | Cirrhosis |
| Strong | (+) or (−) | Any | Any | Any | APRI >2 | |
| Strong | (+) or (−) | >20,000 | >ULN | Any | Particularly if age >30 years |
Abbreviations: AASLD, American Association for the Study of Liver Disease; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; EASL, European Association for the Study of the Liver; HBV, Hepatitis B Virus; ULN, upper limit of normal; WHO, World Health Organization.
a
ULN not specified in the EASL guidelines, local ULN specified at 40 IU/L for both sexes (also applied for WHO treatment rules). ULN of 35 IU/L (males) and 25 IU/L (females) recommended as per AASLD guideline to guide management decisions.
b
Indication could not be considered in this retrospective analysis.